International project aims to develop new HIV vaccines

Companies from the UK, US and France are working together to develop a new vaccine for HIV.

Abzena subsidiary Antitope, based in Cambridge, UK, Dallas-based Baylor Institute for Immunology Research and France's research group INSERM have started collaborating to produce manufacturing cell lines for potential vaccines.

Despite recent research from the University of Oxford in the UK highlighting a possible weakening in the HIV virus, the international project aims to provide better protection for those at risk.

INSERM has been working with the National Agency for Research on AIDS and Hepatitis and the Baylor Institute (BIIR) to develop better approaches for tackling HIV. This has included using extensive preclinical data to assess the immunogenicity of the candidate vaccines.

Antitope will work with the organisations to produce cell lines for critical proteins that can be used in the process.

Dr Gerard Zurawski, co-director of BIIR and director of its Center for Biotechnology, said: “We are excited to be part of this international team that is developing potential new therapeutic options for patients with HIV.”

Posted by Martine WardADNFCR-2094-ID-801769790-ADNFCR